Skip to main content

Table 2 Backward stepwise (Wald) regression analysis

From: Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)

Variable

UPCR High (≥ 2) or Low (<  2)

OR (95% CI)

P value

Step 1

 Age ≥ 60

3.345 (0.407–27.488)

0.261

 Sex Male

0.584 (0.138–2.481)

0.584

 ECOG PS ≥ 1

0.834 (0.187–3.730)

0.813

 Body Weight High (≥ 52.45 kg)

4.415 (1.025–19.020)

0.046

 Primary Site Colorectal vs Gastric

4.093 (0.220–76.242)

0.345

 Used anti-VEGF/Ri Bev vs Ram/AFL

0.358 (0.032–4.054)

0.407

 History of anti-VEGF/Ri YES or NO

0.895 (0.166–4.821)

0.897

 Use of anti-hypertensive agents YES or NO

1.235 (0.366–4.167)

0.734

Step 8

 Body Weight High (≥ 52.45 kg)

3.825 (1.148–12.741)

0.029

  1. Abbreviations: AFL aflibercept, anti-VEGF/Ri anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors, Bev bevacizumab, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group Performance Status Scale, OR odds ratio, Ram ramucirumab, UPCR a single urine protein/creatinine ratio, QV a qualitative value test